Article Figures & Data

Tables

Characteristics of current users and nonusers of lipid-lowering medications, men in ARIC at visit 4 (1996–1999)

All men

Black men

White men

Current lipid-lowering drug use at visit 4 (1996–1999)

No

Yes

No

Yes

No

Yes

N

3,934

953

836

105

3,098

848

Age (years)

63

64

62

63

63

64

Black (%)

21.3

11.0

–

–

–

–

Education (%)

Less than high school graduate

20.2

17.3

37.8

34.3

15.4

15.2

High school graduate, vocational school, some college

36.9

38.0

26.7

24.8

39.7

39.6

College graduate, some graduate school, graduate degree

42.7

44.5

35.2

40.0

44.8

45.1

Missing

0.2

0.2

0.3

0.9

0.1

0.1

Height (cm)

176

175

176

176

176

175

BMI (kg/m2)

28.4

29.0

28.3

29.9

28.4

28.9

Waist-to-hip ratio

0.98

0.99

0.96

0.97

0.98

0.99

Cigarette smoking status (%)

Never

31.9

25.5

30.7

33.3

32.2

24.5

Former/quit ≥10 years ago

39.0

48.6

29.2

38.1

41.6

49.9

Current/quit <10 years ago

29.1

25.9

40.1

28.6

26.2

25.6

Diabetes status (%)

No

43.9

35.2

40.9

23.8

44.6

36.5

At risk for diabetes

39.4

39.3

36.1

40.0

40.3

39.3

Undiagnosed diabetes

5.1

4.9

6.7

1.9

4.7

5.3

Diabetes

11.6

20.6

16.3

34.3

10.4

18.9

Ever hypertensive (%)

49.8

66.0

69.0

85.7

44.6

63.6

Ever elevated cholesterol (%)

25.4

54.9

30.3

65.7

24.1

53.5

Baseline health insurance (%)

92.4

95.9

78.8

83.8

96.0

97.4

Values are means or percentages. All characteristics are assessed at visit 4, unless otherwise indicated. Visit 4 was chosen because by this point statins had been on the market for several years and 76% of the lipid-lowering medications used by ARIC participants were statins.

Table 2.

Association of lipid-lowering medication use and duration of use with incident prostate cancer, 6,518 men in ARIC (1990–2012)

Additional Files

Supplementary Data

Supplemental Tables 1 and 2 -
Supplemental Table 1: Association between lipid-lowering medication use and incident
prostate cancer by frequency of routine physical examinations, and among participants
who had health insurance or had private health insurance and/or Medicare, men in ARIC
(1990-2012). Supplemental Table 2: Association between lipid-lowering medication
use and fatal prostate cancer stratified by routine physical examination, and among
participants who had health insurance or had private health insurance and/or Medicare,
men in ARIC (1990-2012)